Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp.(Nasdaq: PHIO) is a clinical stage biopharmaceutical company whose proprietary INTASYL siRNA technology makes our bodies’ immune cells more effective in killing tumor cells. INTASYL is the only self-delivering siRNA technology focused on immuno-oncology therapeutics. Phio was co-founded by a Nobel Laureate for discovery of RNAi. This discovery was leveraged to develop INTASYL, our broadly patented synthetic short interfering RNA (siRNA) drug technology. INTASYL is precisely designed to specifically silence targeted gene in the human body, causing our immune cells to be more effective in killing tumor cells. For additional information, visit the Company's website, #siRNA #RNAi #Phio #immunooncology